# Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

> **NCT04649723** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

## Interventions

- **DRUG:** Rifampin
- **DRUG:** SHR1459

## Key facts

- **NCT ID:** NCT04649723
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649723, "Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04649723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*